

Awards

The Awards Program of SIDP funds research grants and awards in four areas: Research, Practice, Training, and Service. The Awards Program has evolved over the years to respond to the emerging issues in the field of infectious diseases as well as the needs of a growing membership. Previous recipients to 2002 were noted in the SIDP 10 Year Compendium.

RESEARCH AWARDS

Early Career Investigator Award

The Early Career Investigator Award (formerly the Young Investigator Award) Program was the first research award program to be offered by the Society and was developed to foster excellence in infectious diseases pharmacotherapy research among promising new investigators. This award originally provided \$2,500 to fund original research proposals by young investigators who were active members of SIDP and within five years of their terminal educational training, but is now used to recognize the work of outstanding new investigators within seven years of their terminal educational training who are active or associate SIDP members.

2002	P. David Rogers, PharmD, PhD University of Tennessee College of Pharmacy Memphis, TN
2003	Russell Lewis, PharmD University of Houston College of Pharmacy Houston, TX
2004	Marnie Peterson, PharmD, PhD University of Minnesota College of Pharmacy Minneapolis, MN
2005	Scott R. Penzak, PharmD National Institutes of Health Bethesda, MD
2006	Vincent Tam, PharmD University of Houston College of Pharmacy Houston, TX
2007	Manjunath (Amit) P. Pai, PharmD University of New Mexico College of Pharmacy Albuquerque, NM
2008	Thomas Lodise, PharmD Albany College of Pharmacy and Health Sciences Albany, NY
2009	Nathan P. Wiederhold, PharmD University of Texas at Austin College of Pharmacy Austin, TX

2010	Kerry LaPlante, PharmD University of Rhode Island College of Pharmacy Kingston, RI
2011	Christopher Frei, PharmD, M.S. University of Texas at Austin College of Pharmacy Austin, TX
2012	Marc H. Scheetz, PharmD, M.Sc. Midwestern University Chicago College of Pharmacy Downers Grove, IL
2013	Warren E. Rose, PharmD University of Wisconsin School of Pharmacy Madison, WI
2014	Steven Leonard, PharmD Ohio Northern University Raabe College of Pharmacy Ada, OH
2015	Nimish Patel, PharmD, PhD Albany College of Pharmacy and Health Sciences Albany, NY
2016	Ryan Shields, PharmD, MS University of Pittsburgh Pittsburgh, PA
2017	Elizabeth Hirsch, PharmD University of Minnesota Minneapolis, MN
2018	Brian J. Werth, PharmD University of Washington School of Pharmacy Seattle, WA
2019	N. Jim Rhodes, PharmD, MSc Midwestern University College of Pharmacy Downers Grove, Illinois
2020	Kelly R. Reveles, PharmD, PhD, BCPS University of Texas Health Science Center at San Antonio San Antonio, TX
2021	Melanie Nicol, PharmD, PhD University of Minnesota College of Pharmacy Minneapolis, MN
2022	Kimberly Claeys, PharmD, BCPS University of Maryland School of Pharmacy Baltimore, MD
2023	Zackery Bulman, PharmD Univeristy of Illinois Chicago Chicago, IL

Infectious Diseases Pharmacotherapy Paper of the Year Award

In 1999, the Infectious Diseases Pharmacotherapy Paper of the Year Award was established to recognize an outstanding contribution to the professional literature which has a significant potential impact on infectious diseases practice and/or research. It is conferred each year to one individual from the Society. Funding of \$1,000 per award has been provided in the past by Rhone-Poulenc Rorer Pharmaceuticals and Aventis Pharmaceuticals.

2002	Annie Wong-Beringer, PharmD Western University College of Pharmacy Pomona, CA	Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> with reduced susceptibility to ceftazidime. <i>Clin Infect Dis</i> . 2002;34:135-46.
2003	Paul J. Weidle, PharmD, M.P.H. Centers for Disease Control and Prevention Atlanta, GA	Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. <i>Lancet</i> . 2002;360:34-40.
2004	P. David Rogers, PharmD, PhD University of Tennessee College of Pharmacy Memphis, TN	Rogers PD, Barker KS. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in <i>Candida albicans</i> clinical isolates. <i>Antimicrob Agents Chemother</i> . 2003;47:1220-7.
2005	Angela Kashuba, PharmD University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, NC	Kashuba AD, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. <i>AIDS</i> . 2005;19:145-52.
2006	Robert Owens, PharmD Maine Medical Center Portland, ME	McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of <i>Clostridium difficile</i> . <i>N Engl J Med</i> . 2005;353:2433-41.
2007	Kevin Garey, PharmD, M.S. University of Houston College of Pharmacy Houston, TX	Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. <i>Clin Infect Dis</i> . 2006;43:25-31.
2008	Annie Wong-Beringer, PharmD University of Southern California School of Pharmacy Los Angeles, CA	Hidayat LK, Hsu DI, Quist R, et al. High-dose Vancomycin therapy for methicillin-resistant <i>Staphylococcus aureus</i> infections: efficacy and toxicity. <i>Arch Intern Med</i> . 2006;166:2138-44.
2009	Chris A. Gentry, PharmD Oklahoma City VA Medical Center Oklahoma City, OK	Gentry CA, Gross KB, Sud B, Drevets DA. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. <i>Crit Care Med</i> . 2009;37:19-25.

2010	Thomas Lodise, PharmD Albany College of Pharmacy and Health Sciences Albany, NY	Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. <i>Clin Infect Dis.</i> 2009;49:507-14.
2011	Ravina Kullar, PharmD Oregon State University College of Pharmacy Corvallis, OR	Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteremia: support for consensus guidelines suggested targets. <i>Clin Infect Dis.</i> 2011;52:975-81.
2012	Kevin Garey, PharmD, M.S. University of Houston College of Pharmacy Houston, TX	Garey KW, Ghantaji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with <i>Clostridium difficile</i> infection. <i>J Antimicrob Chemother.</i> 2011;66:2850-5.
2013	Manjunath (Amit) P. Pai, PharmD Albany College of Pharmacy and Health Sciences Albany, NY	Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. <i>Pharmacotherapy.</i> 2012;32:856-68.
2014	Vincent Tam, PharmD University of Houston College of Pharmacy Houston, TX	Phe K, Lee Y, McDaniel PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. <i>Antimicrob Agents Chemother.</i> 2014;58:2740-6.
2015	Thomas Lodise, PharmD, PhD Albany College of Pharmacy and Health Sciences Albany, NY	Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant <i>Staphylococcus aureus</i> bloodstream infections: how much is enough? <i>Clin Infect Dis.</i> 2014;59:666-75.
2016	Molly Steed, PharmD, BCPS University of Kansas Kansas City, KS	Britt NS, Potter EM, Patel N, Steed ME. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. <i>Clin Infect Dis.</i> 2015 Sep 15;61(6):871-8. PMID: 26063715.
2017	Mackenzie Cottrell, PharmD, MS UNC Eshelman School of Pharmacy Chapel Hill, NC	Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, Nelson JA, Kashuba AD. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. <i>J Infect Dis</i> 2016;214:55-64
2018	Katie Suda, PharmD, MS University of Pittsburgh Pittsburgh, PA	SudaKJ, Hicks LA, Roberts RM, HunklerRJ, MatusiakLM, SchumockGT. Antibiotic expenditures by medication, class, and healthcare setting in the United States, 2010-2015. <i>Clin Infect Dis.</i> 2018 Jan 6;66(2):185-190.

2019	Ryan L. Crass, PharmD University of Michigan Ann Arbor, MI	Crass RL, Rodvold KA, Mueller BA, Pai MP. Renal Dosing of Antibiotics: Are We Jumping the Gun? <i>Clinical Infectious Diseases</i> 2019 May 1;68(9):1596-602.
2020	Thomas Lodise, PharmD, PhD Albany College of Pharmacy and Health Sciences Albany, NY	Lodise TP, Rosenkranz SL, Finnemyer M, et al. The emperor's new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with MRSA bloodstream infections (PROVIDE). <i>Clin Infect Dis</i> 2020;70:1536–46.
2021	Sara Alosaimy, PharmD, BCPS, AAHIVP Wayne State University/Anti-Infective Research Lab Detroit, MI	Alosaimy S, Murray KP, Zasowski EJ, Morrisette T, Lagnf AM, Lodise TP, Rybak MJ. Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant <i>Staphylococcus aureus</i> Complicated Skin and Soft Tissue Infections. <i>Clin Infect Dis</i> 2020 July 27 th online ahead of print.
2022	Lynn Wardlow, PharmD, MBA, MS, BCIDP, AAHIVP The Ohio State University Wexner Medical Center Columbus, OH	Nichols CN, Wardlow LC, Coe KE, Sobhanie MME. Clinical Outcomes with Definitive Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia with Retained Daptomycin and Ceftaroline Combination Therapy vs De-escalation to Monotherapy with Vancomycin, Daptomycin, or Ceftaroline. <i>Open For Infect Dis</i> . 2021;8(7):ofab327. doi: 10.1093/ofid/ofab327
2023	Nicholas Mercuro, PharmD, BCIDP Maine Medical Center Portland, ME	Mercuro NJ, Medler CJ, Kenney RM, et al. Pharmacist-Driven Transitions of Care Practice Model for Prescribing Oral Antimicrobials at Hospital Discharge. <i>JAMA Netw Open</i> . 2022;5(5):e2211331. Published 2022 May 2. doi:10.1001/jamanetworkopen.2022.11331

PRACTICE AWARDS

Outstanding Clinician Award

In 1999, the Outstanding Clinician Award was implemented to recognize an SIDP member with exemplary skills as a clinical practitioner and educator in infectious diseases pharmacotherapy. Expertise was demonstrated by at least five years of clinical practice, maintenance of an active patient-care service responsibility, and other significant contributions, e.g. development of innovative services, documentation of benefits, and promotion of safe, effective, rationale use of antimicrobials. Funding of \$1,000 per award has been provided in the past by Rhone-Poulenc Rorer Pharmaceuticals and Aventis Pharmaceuticals.

2002	Alice Pau, PharmD National Institutes of Allergy and Infectious Diseases Bethesda, MD
2003	Larry Mole, PharmD U.S. Department of Veterans Affairs, Center for Quality Management in Public Health Palo Alto, CA
2004	Alexandra Hilts, PharmD University of Colorado Hospital University of Colorado Health Science Center School of Medicine University of Colorado Health Science Center School of Pharmacy Aurora, CO
2005	Craig A. Martin, PharmD University of Kentucky Chandler Medical Center University of Kentucky College of Pharmacy Lexington, KY
2006	James S. Lewis, PharmD University of Texas Health Sciences Center at San Antonio San Antonio, TX
2007	Douglas Slain, PharmD West Virginia University School of Pharmacy Morgantown, WV
2008	Michael Postelnick, R.Ph. Northwestern Memorial Hospital Chicago, IL
2009	Sharon M. Erdman, PharmD Wishard Health Services Purdue University School of Pharmacy West Lafayette, IN
2010	Ben Lomaestro, PharmD Albany Medical Center Hospital Albany, NY

2012	Susan L. Davis, PharmD Henry Ford Hospital Wayne State University College of Pharmacy and Health Sciences Detroit, MI
2013	Brian Potoski, PharmD UPMC Presbyterian Hospital University of Pittsburgh School of Pharmacy Pittsburgh, PA
2014	Kelly Echevarria, PharmD South Texas Veterans Health Care System University of Texas Health Science Center at San Antonio University of Texas at Austin College of Pharmacy San Antonio, TX
2015	Jerod L. Nagel, PharmD University of Michigan Health System University of Michigan College of Pharmacy Ann Arbor, MI
2016	Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP University of New Mexico Albuquerque, NM
2017	Jason Pogue, PharmD, BCPS-AQ ID Sinai-Grace Hospital Detroit, MI
2018	Ashley M. Wilde, PharmD, BCPS-AQ ID Norton Healthcare Louisville, KY
2019	Melinda M. Neuhauser, PharmD, MPH, FCCP, FASHP Centers for Disease Control and Prevention
2020	Alan E. Gross, PharmD, BCIDP, BCPS UIC College of Pharmacy Chicago, IL
2021	Curtis Collins, PharmD, MS, BCPS (AQ-ID), BCIDP, FASHP St. Joseph Mercy Health System Ann Arbor, MI
2022	Monica Mahoney, PharmD, BCPS, BCIDP, FCCP Beth Israel Deaconess Medical Center Boston, MA

2023

Julie Ann Justo, PharmD, MS, FIDSA, BCPS
Dartmouth Hitchcock Medical Center
Lebanon, NH

Gita Patel Best Practice Recognition Award

In 2013, the Gita Patel Best Practice Award was established in honor of Dr. Gita Wasan Patel to recognize an SIDP member who implemented and documented the impact of an innovative or collaborative “best practice” initiative to improve care in patients with infectious diseases. These included development of novel services to deliver quality care or implementation of guidelines or pathways. Dr. Patel demonstrated passion for optimal patient care in infectious diseases despite no formal training in the field. Preference for this award was given to similar applicants in the community setting or to those who did not receive salary support dedicated to research. Formal infectious diseases training was also not required. Funding of \$1,500 per award has been provided in the past by Cubist Pharmaceuticals.

2013	Natalie Boyd, PharmD, M.S. University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio San Antonio, TX
2014	Paulina Deming, PharmD University of New Mexico College of Pharmacy Albuquerque, NM
2016	Melissa Badowski, PharmD, BCPS, AAHIVP University of Illinois at Chicago Chicago, IL
2018	Elias B. Chahine, PharmD, FCCP, FASCP, FFSHP, BCPS, BCIDP Palm Beach Atlantic University Wellington Regional Medical Center
2019	Timothy Gauthier, PharmD, BCPS-AQ ID Baptist Health South Florida Coral Gables, FL
2020	Bruce M. Jones, PharmD, BCPS Saint Joseph's/Candler Health System Savannah, Georgia
2021	Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP Loma Linda University School of Pharmacy Loma Linda, CA
2022	Keenan L Ryan, PharmD, PhC University of New Mexico Hospitals Albuquerque, NM
2023	Ashley Wilde, PharmD, BCIDP Norton Healthcare Louisville, KY

SERVICE AWARDS

Distinguished Service Award

The Distinguished Service Award was established to honor an individual with outstanding and sustained service to the Society. The award was given only when a particularly noteworthy candidate was identified as providing outstanding contributions and/or ensuring the advancement of the goals of the Society via service which far exceed the usual devotion of time, energy, or material goods (e.g. at least ten years of service). The selection committee for this award included SIDP Board members who were not involved in the pharmacist's nomination process.

2009	Melinda Neuhauser, PharmD, M.P.H. Pharmacy Benefit Management Strategic Healthcare Group, U.S. Department of Veterans Affairs Hines, IL
2011	<i>The "Founding Fathers"</i> Steven L. Barriere, PharmD Theravance, Inc. John Bosso, PharmD South Carolina College of Pharmacy – MUSC Campus Michael Dudley, PharmD Rempex Pharmaceuticals Bruce Kreter, PharmD Bristol-Myers Squibb Ron E. Polk, PharmD Virginia Commonwealth University School of Pharmacy Randall Prince, PharmD, PhD University of Houston College of Pharmacy
2015	Vanthida Huang, PharmD, B.S.Pharm. Midwestern University College of Pharmacy – Glendale Glendale, AZ
2022	Kristi Kuper, PharmD, BCPS, FIDSA Pfizer Houston, TX
2023	Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS Temple University/Temple University Hospital Philadelphia, PA

MENTOR AWARDS

Outstanding Mentor Award

In 2022, the Outstanding Mentor Award was established to recognize an individual who has made significant and sustained contributions to the professional development of others, including students, post-doctoral trainees and colleagues. The people recognized by this award have exemplified outstanding mentorship through a dedication to the personal and professional growth of the mentees; guiding, inspiring and empowering the mentees in their career development; demonstrating a sustained commitment to increasing diversity, equity, and inclusion as a mentor; and demonstrating a sustained commitment to advisees over time.

2022	Annie Wong-Beringer, PharmD, FIDSA University of Southern California, School of Pharmacy Los Angeles, CA
2023	Larry Danziger, PharmD, FIDSA University of Illinois at Chicago, College of Pharmacy Chicago, IL

FELLOWSHIP OF THE SOCIETY OF INFECTIOUS DISEASES PHARMACISTS (FIDP)

The Fellowship distinction was developed to recognize outstanding SIDP members who have made a significant and sustained contribution to the area of infectious diseases and the mission of SIDP. Recipients demonstrate a commitment to promoting the appropriate use of antimicrobials for the prevention and management of infectious diseases through leadership and collaboration in infectious diseases practice, education, research, and advocacy.

2017	David S. Burgess, PharmD, FCCP, FIDP Peggy L. Carver, PHARM.D, FCCP, FIDP Richard H. Drew, PharmD, MS, FCCP, FIDP Elizabeth D. Hermsen, PharmD, MBA, BCPS-AQ(ID), FIDP Michael Klepser, PharmD, FCCP, FIDP Joseph L. Kuti, PharmD, FIDP Michael J. Rybak, PharmD, MPH, PhD, FIDP
2018	Steven L. Barriere, PharmD, FIDSA, FCCP, FIDP David T. Bearden, PharmD, FIDP John A. Bosso, PharmD, FIDSA, FCCP, FIDP Douglas N. Fish, PharmD, FCCM, FCCP, BCCCP, BCPS (AQ-ID), FIDP Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, FIDP Paul O. Gubbins, PharmD, FCCP, FIDP John F. Mohr III, PharmD, FIDP
2019	Susan Davis, PharmD Melinda Neuhauser, PharmD, MPH, FCCP, FASHP Sharon M. Erdman, PharmD Randall A. Prince, PharmD, FCP, FCCP, FIDSA
2020	Elizabeth S. Dodds Ashley, PharmD, MHS, FCCP, FIDP, BCPS Amy Lynn Pakyz, PharmD, MS, PhD, FIDP
2021	Kerry L. LaPlante, PharmD, FCCP, FIDSA, FIDP Peggy S. McKinnon, PharmD, FCCP, FIDP
2022	Monica Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDP Jason Pogue, PharmD, BCIDP, FIDP
2023	Emily Heil, PharmD, MS, BCIDP, AAHIVP, FIDP Elizabeth B. Hirsch, PharmD, FCCP, FIDSA, FIDP

GRANT AWARDS

In collaboration with partners in industry the Society has invested heavily in research funding and advanced training of infectious disease pharmacists. Over the last 15 years SIDP has distributed over \$352,500 in grant support which has funded 42 investigators. The majority of this support has gone to funding junior investigators and has helped to kick-start many successful academic careers.

Award and Grant:

2000 – 2001	George Allen, PharmD Wayne State University/Anti-Infective Research Lab Detroit, MI	Evaluation of the mutant prevention concentration (MPC) as a measure of fluoroquinolone potency in clinical strains of <i>Streptococcus pneumoniae</i> with or without preexisting mutations in the genes encoding for topoisomerase IV
2000 – 2001	Erika Ernst, PharmD University of Iowa Iowa City, IA	Impact of resistance on the clinical outcomes in patients with acute uncomplicated cystitis
2000 – 2001	Kevin Garey, PharmD University of Chicago Chicago, IL	Immunosurveillance of active TB by breath condensate
2000 – 2001	Paul Gubbins, PharmD University of Arkansas Fayetteville, AR	Determining the influence of intestinal CYP3A4 and P-glycoprotein on the oral bioavailability of itraconazole capsules
2000 – 2001	Chris Rathbun, PharmD University of Oklahoma Little Rock, OK	Impact of a pharmacist-operated clinic on adherence and treatment outcomes in patients with HIV infection
2000 – 2001	Patty Fan-Harvard, PharmD Ohio State University Columbus, OH	Determination of nelfinavir binding to cellular retinoic acid-binding protein (CRABP1) in placental trophoblasts
2001 – 2002	Russell Lewis University of Houston	Immunopharmacodynamics of Amphotericin B in invasive pulmonary aspergillosis
2001 – 2002	Susan Pendland University of Illinois	Activity of Botanicals against Yeasts
2001 – 2002	Jeffrey Aeshlimann University of Connecticut	Impact of efflux on <i>P. aeruginosa</i> outcomes
2002 – 2003 Aventis	Russell Lewis, PharmD University of Houston	Comparison of Etest, chequerboard dilution and time—kill studies for the detection of synergy or antagonism between antifungal agents tested against <i>Candida</i> species

2002 – 2003 Abbott	Susan Penland University of Illinois	
2002 2003 Aventis	Jeffrey Aeschlimann University of Connecticut	
2003 – 2004 Astrazeneca	David Burgess, PharmD University of Texas Health Science Center	Nanoparticle itraconazole pulmonary delivery
2003-2004 Abbott Research Award	Elizabeth Dodds-Ashley, PharmD Duke University	Characterization of aerosolized amphotericin B lipid complex lung distribution
2004-2005 Bayer Research Award	Mary Hayney, PharmD University of Wisconsin Madison, WI	T cell response to hepatitis B vaccine
2003-2004 Wyeth Research Award	Tom Lodise, PharmD Albany College of Pharmacy Albany, NY	Outcomes of extended interval piperacillin/tazobactam
2003-2004 Wyeth Research Award	Nathan Wiederhold, PharmD University of Houston Houston, TX	<i>In vivo</i> pharmacodynamics of amphotericin B in invasive aspergillus
2003-2004 Aventis Research award	G. Christopher Wood, PharmD University of Tennessee Health Systems	Genetic predisposition for nosocomial pneumonia
2004 -2005 Bayer	Mary Hayney, PharmD University of Wisconsin	T cell response to hepatitis B vaccine
2004 – 2005 Abbott	Pete Anderson University of Colorado Denver	Antiretroviral pharmacology and drug transporter genetics
2004 – 2005 Briston- Myers Squidd	Christopher Frei VA Biomedical Research Foundation San Antonio	Validation of measures for retention in expert care in Veterans Health Administration patients with HIV
2004 – 2005 Wyeth	Kevin Garey University Houston	Type III Secretory Proteins and <i>Pseudomonas aeruginosa</i>
2005 – 2006 Pfzier	Sarah Robertson, PharmD NIH Clinical Center Bethesda, MD	Association of efavirenz metabolism and CYP2B6 genotype

2005 – 2006 Pfizer	George P. Allen, PharmD Oregon State University Portland, OR	<i>In vitro</i> evaluation of resistance induction in CA-MRSA
2005 – 2006 Wyeth	Rose Jung, PharmD University of Colorado Denver, CO	Evaluation of efflux in MDR <i>Pseudomonas aeruginosa</i>
2005 – 2006 Pfizer	Amit Pai, PharmD University of New Mexico Albuquerque, NM	Pharmacodynamic evaluation of flucytosine, voriconazole, and micafungin in an <i>in vivo</i> model of <i>Candida albicans</i> infective endocarditis
2005 – 2006	Vincent Tam, PharmD University of Houston Houston, TX	Mini-sabbatical
2005 – 2006	David Burgess University of Texas Houston, TX	Mini-sabbatical
2006 – 2007	Vincent Tam, PharmD University of Houston Houston, TX	Modeling combination antimicrobial therapy
2006 – 2007	Nathan Weiderhold, PharmD University of Texas Houston, TX	Cell wall integrity pathway and clinical attenuation of Echinocandin activity
2007 – 2008	David J. Feola, PharmD University of Kentucky Lexington, KY	<i>In vivo</i> impact of azithromycin on macrophage phenotype in <i>Pseudomonas aeruginosa</i> infection
2007 – 2008 Astellas	Paulina Deming, PharmD, PHC New Mexico College of Pharmacy Albuquerque, NM	MRSA strains as an independent risk factor in hospitalized patient outcomes
2007 – 2008 AB Biodisk	Ayman Noreddin, PhD Regents of the University of Minnesota	A high-throughput biofilm model of treatment efficacy for catheter-related UTIs
2007 – 2008 ViroPharma	Kevin Garey, PharmD, MS University of Houston, College of Pharmacy Houston, TX	Host cytokine polymorphism determinants for <i>C. difficile</i> associated diarrhea
2008 – 2009 SIDP	Joseph Swanson, PharmD, BCPS University of Tennessee Memphis, TN	Pulmonary biomarkers in patients with and without VAP

2008 – 2009 Astellas	Warren Rose, PharmD University of Wisconsin Madison, WI	Clinical and microbiological evaluation of reduced vancomycin bactericidal activity in MRSA bacteremia
2008 – 2009 ViroPharma	Mary S. Hayney, PharmD, MPH, BCPS University of Wisconsin Madison, WI	T cell responses to CMV antigen for lung transplant recipients
2009 – 2010 Atellas	Stephanie Flowers, PharmD University of Tennessee Memphis, TN	The role of mutations in FCR1, CRZ2, and ERG11 on azole resistance in <i>Candida albicans</i>
2009 – 2010	Julie Dumond, PharmD, BCPS, AAHIVE University of North Carolina Chapel Hill, NC	Atripla pharmacokinetics in the aging HIV-infected population
2010 – 2011 Astellas	Carla Jean Walraven, PharmD University of New Mexico Albuquerque, NM	Echinocandin antifungal and paradoxical activity in <i>Candida albicans</i> biofilms
2010 – 2011	Kristin Darin, PharmD Northwestern University Chicago, IL	A pilot study to evaluate rapid HIV screening in a pharmacy-based setting
2011 – 2012	Marc Scheetz, PharmD Midwestern University – Chicago Chicago, IL	Clinical outcomes of KPC bloodstream infections
2012 – 2013	Betsy Hirsch, PharmD, BCPS Northeastern University Boston, MA	Activity of fosfomycin against contemporary urinary pathogens
2013 – 2014	Molly Steed, PharmD University of Kansas Kansas City, KS	<i>Staphylococcus aureus</i> SCV and hVISA in cystic fibrosis
2014 – 2015	Brian Werth, PharmD University of Washington	Rapid detection of heterogeneous vancomycin intermediate <i>Staphylococcus aureus</i> (hVISA) by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF)
2014 – 2015	Joseph Carreno, PharmD Albany College of Pharmacy and Health Sciences Albany, NY	Validation of a Bayesian approach to estimate vancomycin exposure in obese patients